Key Takeaways:
- New FDA analysis of 137,000+ cases reveals each GLP-1 drug has distinct safety patterns beyond typical nausea and constipation
- Semaglutide (Ozempic, Wegovy) shows higher rates of psychiatric events including panic attacks and suicidal behavior
- Female patients face unique risks including menstrual bleeding and reproductive system issues across all GLP-1s
- Individual safety profiles should guide medication selection, not just cost and effectiveness
Largest Safety Analysis of GLP-1s Reveals Surprising Patterns
A comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database from 2012 to 2025 has revealed distinct safety profiles across different GLP-1 medications, examining over 137,000 cases involving five commonly prescribed drugs: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide. The findings, published April 2 in the journal Obesity, challenge the assumption that all GLP-1s carry identical risks.
With the rapid uptake of GLP-1s, postmarketing surveillance is essential to detecting safety signals not captured in clinical trials. This analysis provides the most comprehensive real-world safety picture to date, analyzing adverse events by specific medication, indication (diabetes versus weight loss), and patient demographics.
The analysis included 137,451 cases involving GLP-1s, most often for type 2 diabetes treatment (42,570 cases) and weight control or obesity (12,311 cases). Researchers used sophisticated statistical methods to identify safety signals that go beyond what clinical trials typically capture.
Semaglutide Shows Unique Psychiatric Risk Pattern
Perhaps the most concerning finding involves semaglutide (the active ingredient in Ozempic and Wegovy), which showed a distinct pattern of psychiatric adverse events. Semaglutide was associated with more gastrointestinal and psychiatric events, dulaglutide and exenatide with more deaths and hospitalizations, and liraglutide and exenatide with more neoplasm-related reports.
For people using GLP-1s specifically for weight management, the psychiatric risks were particularly pronounced. For weight control or obesity, GLP-1 use was associated with general nutritional disorders (ROR, 3.08), sensory abnormalities (ROR, 6.28), panic attacks and disorders (ROR, 4.63), suicidal or self-injurious behavior (ROR, 4.64), depressive disorders (ROR, 2.79), immune‑associated conditions (ROR, 3.13), and eating disorders (ROR, 2.53).
These findings add context to ongoing discussions about mental health effects of GLP-1 medications. While the FDA recently removed suicide warnings from some GLP-1 labels based on clinical trial data, this real-world analysis suggests the picture may be more complex, particularly for weight management uses.
Women Face Additional Reproductive Risks
The analysis revealed gender-specific safety patterns that haven't been widely discussed. Among female patients, GLP‑1s were linked to the reporting of menstrual bleeding, ovarian or fallopian cysts and neoplasms, and reproductive system hemorrhages.
These reproductive system effects represent an important consideration for women of childbearing age who are considering GLP-1 treatment. The findings suggest healthcare providers should discuss these potential risks with female patients and monitor for reproductive system changes during treatment.
For women already taking GLP-1 medications, these findings don't indicate you need to stop treatment immediately. However, you may want to track any changes in your menstrual cycle or reproductive health and discuss them with your doctor during regular check-ups.
Each GLP-1 Drug Shows Distinct Safety Profile
Individual GLP-1s showed varying toxicity profiles. Semaglutide was associated with more gastrointestinal and psychiatric events, dulaglutide and exenatide with more deaths and hospitalizations, and liraglutide and exenatide with more neoplasm-related reports. This challenges the common clinical practice of treating all GLP-1s as interchangeable from a safety perspective.
The differences extend beyond the well-known gastrointestinal effects. Gastrointestinal disorders were common across all GLP-1s. However, when researchers looked at other safety signals, clear patterns emerged that distinguish one medication from another.
For diabetes treatment specifically, the risks differed from weight management uses. The analysis found associations with retinopathies, skin conditions, and even hearing loss that were more prominent in diabetes patients than those using GLP-1s for weight management.
These distinctions become particularly relevant when comparing newer medications like tirzepatide to established options. The data suggests that individual safety profiles may be just as important as effectiveness when making treatment decisions.
How This Changes Clinical Practice
This safety analysis has immediate implications for how doctors prescribe and monitor GLP-1 medications. "As millions of people are taking GLP-1s for weight control and obesity treatment worldwide, clinicians should be vigilant in monitoring for unanticipated long-term adverse effects," the study authors wrote.
The findings suggest that choosing between different GLP-1 medications shouldn't be based solely on efficacy and cost. Individual safety profiles may make certain medications more appropriate for specific individuals based on their medical history and risk factors.
For people with a history of psychiatric conditions, these findings raise important questions about medication selection. Similarly, the reproductive system findings for women suggest additional monitoring may be warranted.
Healthcare providers may need to adjust their prescribing patterns, considering not only which GLP-1 might be most effective for weight loss or diabetes management, but which carries the lowest risk profile for each person's unique circumstances.
What This Means for You
If you're currently taking a GLP-1 medication or considering starting one, this analysis doesn't suggest you should stop treatment. Rather, it emphasizes the importance of individualized care and ongoing monitoring.
Discuss your specific risk factors with your healthcare provider, especially if you're a woman of childbearing age or have a history of psychiatric conditions. The safety differences between medications mean your doctor may recommend one GLP-1 over another based on your personal health profile.
When exploring your options through telehealth providers or local clinics, make sure to discuss these safety findings. You can also use our cost comparison tool to evaluate different GLP-1 medications while keeping these safety considerations in mind. Remember that the lowest-cost option may not always be the best choice when individual safety profiles are considered.
If you're already taking a GLP-1, don't stop without consulting your healthcare provider. Instead, use this information to have a more informed conversation about whether your current medication is the best fit for your individual risk profile.
Sources
- FDA Data Reveal Different Risks for GLP-1s - Medscape analysis of FDA adverse event data published April 2, 2026
- Analysis of real-world pharmacovigilance data shows distinct adverse event patterns across GLP-1 indications - Obesity journal publication of the comprehensive safety analysis